Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth to introduce Conbrizatm in Europe

Wyeth to introduce Conbrizatm in Europe

29th April 2009

Wyeth intends to introduce Conbrizatm (bazedoxifene) into certain European markets now it has received marketing authorisation.

The selective oestrogen receptor modulator has been permitted by the European Commission to treat osteoporosis in postmenopausal women.

Over 75 million people are affected by the bone condition across Europe, the US and Japan – and Wyeth is one of the first companies to have followed the World Health Organisation’s treatment guidelines of the illness while developing the medication.

Dr Gary L Stiles, executive vice-president and chief medical officer of the company’s pharmaceutical division, explained Conbrizatm was shown to significantly lower bone problems in females who were at increased risk of osteoporotic fracture.

“Importantly, the analyses also showed that the higher a woman’s risk of a fracture, the greater the protection she received with Conbriza therapy,” he remarked.

Wyeth and Elan announced earlier this month they were discontinuing the highest dose regimen of bapineuzumab in a phase III clinical trial to examine its effect in patients with mild to moderate Alzheimer’s disease.

The investigations of the other two measurements are to continue.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.